EloraTZP: Lilly's Eloralintide + Tirzepatide Combo Explained

What is EloraTZP, and why is everyone suddenly searching for it? EloraTZP is Eli Lilly's experimental combination of eloralintide, a weekly amylin shot, and tirzepatide, the medicine in Zepbound and Mounjaro. In a 48-week trial in adults with obesity and type 2 diabetes, the highest dose led to 23.3% average weight loss. That beat tirzepatide 15 mg alone, which gave 14.8%. It is not approved, and a large Phase 3 trial is set to start in December 2026.

The news this week is that the Phase 3 trial is now public. Korean business outlet Chosunbiz reported on October 25, 2026 that Lilly is moving the amylin combo into Phase 3. The trial, called AMPLIFY-1, appeared on ClinicalTrials.gov on October 19. Here is what EloraTZP is, what the data show and what it means for you.

What is EloraTZP? Eloralintide with tirzepatide

The name is short for eloralintide plus TirZePatide. Each part works in a different way:

• Eloralintide (code LY3841136) copies amylin, a hormone your pancreas releases along with insulin after you eat. Amylin slows how fast your stomach empties and tells your brain you are full. Eloralintide is a once-weekly shot.
• Tirzepatide (LY3298176) acts on two gut hormone receptors, GIP and GLP-1. It is already approved as Zepbound for weight and Mounjaro for type 2 diabetes. Our Mounjaro guide explains how it works.

The idea is that hitting amylin, GIP and GLP-1 together cuts appetite more than any one of them. In the Phase 2b trial, people got two separate shots. For Phase 3, Lilly made a single co-formulated shot, listed in the trial record as LY900043.

EloraTZP trial results: the Phase 2b numbers

Lilly presented the trial (NCT06603571) at the EASD meeting in Milan and announced it on September 30, 2026. It enrolled 367 adults in the US and Argentina who had obesity or overweight plus type 2 diabetes. On average they started at 232.4 lb with an A1C of 8.1%.

Two things help you read this table:

1. These are "efficacy estimand" results. That means they estimate what happens if everyone stayed on treatment for all 48 weeks. Results counting everyone who started, including people who quit, are usually lower. Lilly did not release those.
2. People with type 2 diabetes usually lose less weight on these drugs than people without it. That is why tirzepatide 15 mg gave 14.8% here, lower than in trials of people without diabetes.

Eloralintide alone has been tested in people without diabetes too. In a Phase 2 trial published in The Lancet in 2025, 263 adults lost up to 20.1% of their weight in 48 weeks, versus 0.4% on placebo. Eloralintide by itself is already in Phase 3.

EloraTZP side effects and the dropout question

This is the part to watch. Lilly says the most common side effects were stomach and gut problems, mostly mild or moderate and mostly during the weeks when the dose was going up. They happened more often with the combination than with either drug alone.

The share of people who stopped because of side effects tells the story:

Up to about 1 in 4 people quitting is high. Lilly says Phase 3 will use an "optimized escalation schedule," meaning slower or gentler dose steps, to try to bring that down. For help with the side effects you can control today, see our GLP-1 nausea guide.

What about muscle? The question nobody has answered yet

Losing 20% or more of your body weight raises a fair question: how much of it is muscle? Lilly's announcement did not report body scans or lean mass for EloraTZP. Any drug that makes you eat much less can cost you some muscle unless you eat enough protein and do strength work.

That is the part you can work on now, whatever medication you take. Sharpy gives you one daily protein target based on your body, one 20-minute strength workout and a Shape Score that tracks your shape, not just the scale. Our protein target guide shows how the number is set.

EloraTZP phase 3: the AMPLIFY-1 trial

Here is what the ClinicalTrials.gov record (NCT07881432) says, as of October 26, 2026:

• Name: AMPLIFY-1, a Phase 3 study of LY900043 (EloraTZP).
• Who: about 2,115 adults with obesity who do not have type 2 diabetes.
• Groups: five EloraTZP doses, eloralintide alone, tirzepatide alone and placebo, all given as shots under the skin, double-blind.
• Main goal: percent change in body weight at week 100.
• Timing: not yet recruiting. Estimated start December 2026, main results around October 2029.

So even if everything goes well, EloraTZP will not be in pharmacies for years. There is no price and no approval date.

EloraTZP vs retatrutide and CagriSema

People are already searching "EloraTZP vs reta." No trial has put them head to head, and the numbers come from different groups of people over different lengths of time, so they cannot be compared fairly.

CagriSema uses the same basic idea as EloraTZP: an amylin drug plus a GLP-1 drug. Read our CagriSema guide and our retatrutide guide for their own trial results. For a closer look at the other amylin shots, see petrelintide.

The bottom line

EloraTZP is one of the strongest weight loss results Lilly has shown in people with type 2 diabetes. But it is still an experiment, more people quit because of side effects, and Phase 3 has not started enrolling. If you want a medicine now, the approved options are covered in our GLP-1 medication comparison, and your prescriber can help you choose. Whatever you take, Sharpy helps you lose fat, not muscle, with a protein target, a 20-minute workout and a daily Shape Score.

Sources

• Eli Lilly press release: EloraTZP Phase 2b results (PR Newswire, Sep 30, 2026)
• ClinicalTrials.gov: AMPLIFY-1, NCT07881432
• ClinicalTrials.gov: Phase 2b trial, NCT06603571
• The Lancet (2025): eloralintide Phase 2 trial, via PubMed
• Healio: Combining amylin agonist with tirzepatide (Oct 2, 2026)